QELFA: quantitative disposable assay for diagnosis and monitoring of kidney disease

According to a report published in 2012 by NHS Kidney Care, kidney disease costs the NHS
over £1.4 billion, more than breast, lung, colon and skin cancers combined. Using a unique
proprietary technology capable of quantifying protein in urine, this project innovatively
modifies the technology contained in familiar pregnancy tests to deliver a quantitative test of
kidney disease that can be used at near-patient settings. This device could be used by
clinicians to diagnose and stage chronic kidney disease or by patients at home for selfmonitoring.
Moreover, the digital readout of the test enables the automatic and accurate
collation of kidney function readings into a central database using mobile technology.